RECIST 1.1 Solid-Tumor Response Assessment — free guideline decision tool
Turn RECIST 1.1 into a tool: enter the target-lesion sum of diameters (baseline / nadir / current) plus non-target and new-lesion status to derive the target-lesion response (CR/PR/SD/PD) and overall response. Instant, browser-side.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does RECIST 1.1 Solid-Tumor Response Assessment do?
Standardized response read-out for solid-tumor follow-up — oncologic imaging reports and trial eligibility. Lesion measurement and target selection are done by the radiologist.
How is the result calculated?
CR: all target lesions gone, all pathological nodes short axis < 10 mm. PR: SLD ≥30% below baseline. PD: SLD ≥20% above nadir AND ≥5 mm absolute increase (both required), or an unequivocal new lesion. SD: neither PR nor PD.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run RECIST 1.1 Solid-Tumor Response Assessment now
Turn RECIST 1.1 into a tool: enter the target-lesion sum of diameters (baseline / nadir / current) plus non-target and new-lesion status to derive the target-lesion response (CR/PR/SD/PD) and overall response. Instant, browser-side.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.